Resolving DOAC interference on aPTT, PT, and lupus anticoagulant testing by the use of activated carbon

Adcock, 2015, Direct oral anticoagulants (DOACs) in the laboratory: 2015 review, Thromb Res, 136, 7, 10.1016/j.thromres.2015.05.001 Douxfils, 2018, Laboratory testing in patients treated with direct oral anticoagulants: a practical guide for clinicians, J Thromb Haemost, 16, 209, 10.1111/jth.13912 Jacquemin, 2015, The addition of idarucizumab to plasma samples containing dabigatran allows the use of routine coagulation assays for the diagnosis of hemostasis disorders, J Thromb Haemost, 13, 2087, 10.1111/jth.13138 Jacquemin, 2018, The adsorption of dabigatran is as efficient as addition of idarucizumab to neutralize the drug in routine coagulation assays, Int J Lab Hematol, 40, 442, 10.1111/ijlh.12807 Kaatz, 2017, Reversing factor Xa inhibitors – clinical utility of andexanet alfa, J Blood Med, 10.2147/JBM.S121550 Ansell, 2017, Single‐dose ciraparantag safely and completely reverses anticoagulant effects of edoxaban, Thromb Haemost, 117, 238, 10.1160/TH16-03-0224 Levy, 2018, Reversal agents for non‐vitamin K antagonist oral anticoagulants, Nat Rev Cardiol, 15, 273, 10.1038/nrcardio.2017.223 Exner, 2018, Simple method for removing DOACs from plasma samples, Thromb Res, 163, 117, 10.1016/j.thromres.2018.01.047 Favresse, 2018, Evaluation of the DOAC‐Stop® procedure to overcome the effect of DOACs on several thrombophilia screening tests, TH Open, 02, e202, 10.1055/s-0038-1657785 Kopatz, 2018, Use of DOAC Stop for elimination of anticoagulants in the thrombin generation assay, Thromb Res, 170, 97, 10.1016/j.thromres.2018.08.014 Platton, 2018, Influence of DOAC Stop on coagulation assays in samples from patients on rivaroxaban or apixaban, Int J Lab Hematol Wang, 2014, Effect of activated charcoal on apixaban pharmacokinetics in healthy subjects, Am J Cardiovasc Drugs, 14, 147, 10.1007/s40256-013-0055-y Dubois, 2017, Perioperative management of patients on direct oral anticoagulants, Thromb J, 15, 10.1186/s12959-017-0137-1 van Ryn, 2010, Dabigatran etexilate–a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity, Thromb Haemost, 103, 1116, 10.1160/TH09-11-0758 Ollier, 2017, Effect of activated charcoal on rivaroxaban complex absorption, Clin Pharmacokinet, 56, 793, 10.1007/s40262-016-0485-1 Pengo, 2009, Update of the guidelines for lupus anticoagulant detection, J Thromb Haemost, 7, 1737, 10.1111/j.1538-7836.2009.03555.x Westgard, 2016 Juurlink, 2016, Activated charcoal for acute overdose: a reappraisal, Br J Clin Pharmacol, 81, 482, 10.1111/bcp.12793 Cooney, 1977, Heparin adsorption on activated charcoal, Clin Toxicol, 11, 569, 10.3109/15563657708988221 Mowry, 2015, 2014 Annual Report of the American Association of Poison Control Centers’ National Poison Data System (NPDS): 32nd Annual Report, Clin Toxicol, 53, 962, 10.3109/15563650.2015.1102927 Gosselin, 2017, Clinical pearls: laboratory assessments of direct oral anticoagulants (DOACS), Hamostaseologie, 37 van Os, 2011, Detection of lupus anticoagulant in the presence of rivaroxaban using Taipan snake venom time, J Thromb Haemost, 9, 1657, 10.1111/j.1538-7836.2011.04395.x Keeling, 2012, Guidelines on the investigation and management of antiphospholipid syndrome, Br J Haematol, 157, 47, 10.1111/j.1365-2141.2012.09037.x Gosselin, 2015, Determining the effect of freezing on coagulation testing: comparison of results between fresh and once frozen‐thawed plasma, Blood Coagul Fibrinolysis, 26, 69, 10.1097/MBC.0000000000000184